Our Work in Neurology
The multiple sclerosis (MS) market is more dynamic than ever with more than 14 disease-modifying therapies (DMTs) currently available. In addition, evolving attitudes around safety issues balanced with earlier treatment with aggressive therapy has made the competitive environment increasingly complex. With the launch of the first anti-CGRP agent, the migraine market gains a new class which will shift current competitive patterns.
Multiple Sclerosis, Migraine, Rare Neurological Diseases
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with MS and those who are close to them.
Genentech’s Ocrevus Positioning as an Appropriate First-Line Option in Relapsing Remitting Multiple Sclerosis Appears to Be Resonating With a Subset of U.S. Neurologists – September 19, 2018
Spherix Global Insights Announces Real World Audit Abstracts Accepted for Presentation at the 34th Congress of ECTRIMS In Berlin, Germany – August 7, 2018
Recent Chart Audit of New Start Multiple Sclerosis Patients Confirms Dominance of the Oral Class, including Biogen’s Tecfidera, for First-Line Treatment But Finds Monoclonal Antibody Therapies, such as Genentech’s Ocrevus, Emerging as Legitimate Competitors – July 23, 2018
A Paradigm Shift in Disease-Modifying Therapy Treatment Rates for Progressive Forms of Multiple Sclerosis Largely Dependent Upon Genentech’s Ocrevus Prescribing Patterns – June 26, 2018